Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sumaya Verwaltungs
Tegernsee, Bavaria, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Sumaya Verwaltungs is a German investment vehicle and family office for the Strüngmann family, notably Thomas and Andreas Strüngmann, the founders of Hexal. The firm is a prominent investor in the European life sciences and biotechnology sectors, providing long-term capital to innovative healthcare companies. Most famously, Sumaya and related Strüngmann entities were the seed investors and majority shareholders in BioNTech, the developer of the first authorized mRNA COVID-19 vaccine. The company focuses on transformative medical technologies, oncology, and infectious diseases through its extensive portfolio of biotech holdings.
- Industry
- Investors
Beyond the preview
Go deeper on Sumaya Verwaltungs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sumaya Verwaltungs.